Remove 2024 Remove Biosimilars Remove Pharmaceutical Manufacturing
article thumbnail

CPHI & PMEC India expo to be held from Nov 26-28, 2024

Express Pharma

The 17th edition of CPHI & PMEC India, organised by Informa Markets in India, returns in an advanced format, scheduled from November 26-28, 2024, at the India Expo Centre, Greater Noida, Delhi-NCR. India’s pharma industry is on an impressive growth trajectory, expected to reach $65 billion by 2024 and to double to $130 billion by 2030.

article thumbnail

Bayer’s Eylea market grip set to slip as Alvotech biosimilar closes in

Pharmaceutical Technology

Alvotech has moved one step closer to entering the Eylea (aflibercept 2 mg) biosimilar market, after a European Medicines Agency (EMA) panel recommended approval of its copycat biologic. Go deeper with GlobalData Reports LOA and PTSR Model - Aflibercept Biosimilar in Age Related Macular. CucuMberStudio via Shutterstock.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AI-driven drug discovery, precision medicine, and sustainable manufacturing can redefine the pharma industry

Express Pharma

What are the top 3 trends that defined pharma manufacturing in India and globally in 2024? In 2024, the pharmaceutical manufacturing landscape underwent transformative changes, driven by technological innovations, regulatory adaptations, and evolving global demands. and Europe. and Europe.

article thumbnail

Recent Ustekinumab and Denosumab Biosimilars Deals

Big Molecule Watch

On Dec 24, 2024, Bio-Thera Solutions Inc. announced that it has partnered with Tabuk Pharmaceutical Manufacturing Company to commercialize BAT2206, a proposed ustekinumab biosimilar to Jansen’s STELARA, in Saudi Arabia. Also on December 24, 2024, GlycoNex, Inc.

article thumbnail

Pharmaceutical Technology Excellence Awards 2025: i3 Membrane

Pharmaceutical Technology

Can pharma tariffs “Make America Manufacture Again”? This flexibility is particularly beneficial for pharmaceutical manufacturers looking to upgrade their research and discovery processes without overhauling their entire systems. “Great thanks to Pharmaceutical Technology.

article thumbnail

Gross-to-Net Bubble Update: 2023 Pricing Realities at 10 Top Drugmakers

Drug Channels

It’s time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. Insulin has been the first to deflate—and the Humira biosimilar market may be next. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. All rights reserved.

article thumbnail

Changing the PAP Model

Pharmaceutical Commerce

A Further Examination of Pharmacy Benefit Managers Nicholas Saraceno, Editor March 29th 2024 Podcast Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.